FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W203401045> ?p ?o ?g. }

• W203401045 endingPage "543" @default.
• W203401045 startingPage "543" @default.
• W203401045 abstract "Abstract Background HCT cures thalassemia major (TM). In the absence of a family donor, marrow or less frequently umbilical cord blood (UCB) from unrelated donors (URD) has been used. Due to risks of graft rejection, myeloablative preparative regimens are primarily utilized. URD marrow and UCB HCT have 65-90% and 21-74% event free survival (EFS) and rejection rates of 9-17% and 17-57% respectively. The URTH trial was developed in collaboration with the Thalassemia Clinical Research Network (TCRN), National Heart, Lung and Blood Institute (NHLBI), Pediatric Blood and Marrow Transplant Consortium (PBMTC) and New England Research Institutes (NERI) to explore URD HCT for TM as a strategy to expand availability of HCT. It employed reduced intensity conditioning (RIC) as a means to decrease early and late toxicities. The study tested our hypothesis that an immunosuppressive RIC regimen was sufficient for engraftment in children with TM (age > 1 year to < 17 years) after URD HCT. The primary objective was to determine EFS at 1 year after URD marrow or UCB HCT. Methods Patients with transfusion dependent beta thalassemia and a suitable URD (matched at 8/8 HLA-alleles in marrow donors or 5 to 6/6 HLA antigens in UCB donors) were conditioned with hydroxyurea (30mg/kg x 30 days) (day -50 to -21), alemtuzumab (48 mg) (-22 to -19), fludarabine (150 mg/m2) (-8 to -4), thiotepa (8mg/kg) (-4), and melphalan (140mg/m2) (-3). Patients received tacrolimus or cyclosporine with methotrexate and methylprednisone (marrow) or mycophenolate mofetil (UCB) after HCT to prevent graft-versus-host disease (GVHD). Suitable UCB units were defined as having a pre-thaw total nucleated cell content >4.0x10E7/Kg recipient weight. Patients were eligible irrespective of Pesaro classification but the presence of liver fibrosis by histology was an exclusion criterion. Results Twenty-three patients from 11 US centers (11M: 12F) with a median age of 10 years (2–17 years) received unrelated donor allografts: marrow (14) or UCB matched at 6/6 (1) or 5/6 HLA antigens (8). The median follow up time was 12 months (range 120 days-2 years). The median time to neutrophil engraftment was 13 days (range 10-25) and 34 days (range 12-46) after marrow and UCB HCT respectively. The median time to platelet engraftment after marrow and UCB HCT was 24 days (range 18-34) and 54.5 days (range 32-234) respectively. Primary graft rejection occurred in 1 patient (4% of all patients) following UCB HCT and was accompanied by autologous hematopoietic recovery 35 days after HCT. All others had >90% donor chimerism and achieved transfusion independence. There were no late graft rejections. The overall and EFS probabilities were 82% and 78% respectively at the most recent encounter. One patient developed mild VOD which resolved uneventfully. Of 15 patients who had CMV reactivation, 13 responded to pre-emptive therapy and had no progression to CMV disease. The probabilities of grade II-IV and grade III-IV acute GVHD were 30% and 9% respectively. Limited chronic GVHD was noted in 35% of the cohort; 9% developed extensive cGVHD. Four patients died on days 25, 86, 106 and 366. The causes of death included 1) pulmonary hemorrhage associated with CMV, adenovirus, and Pneumocystis jiroveci infections, 2) diffuse alveolar pulmonary hemorrhage, 3) cGVHD with pneumonia associated with CMV and adenovirus infections, and 4) cGVHD with pulmonary failure associated with CMV and EBV infections and presumed central nervous system post-transplantation lymphoproliferative disease. Conclusion HCT after RIC for thalassemia is feasible and sufficient for engraftment after URD marrow and UCB transplantation with survival exceeding 80%. The principal transplant- related complications we observed were early opportunistic viral reactivations; otherwise the preparative regimen was tolerated well with very little early toxicity. Fatal and late viral infections were noted only in the setting of severe GVHD. Patients should be monitored carefully and treated promptly for infectious complications after HCT until there is adequate immune reconstitution. The risk of severe GVHD was low despite unrelated and mismatched (UCB) donor sources. Longer follow up will determine if this regimen can reduce late toxicities. An extension of this trial is ongoing and currently recruiting patients to evaluate additional HCT related and quality of life measures. Disclosures: Neufeld: Shire: Consultancy. Kwiatkowski:Resonance Health: Research Funding; Shire: Consultancy. Thompson:Novartis: Consultancy, Research Funding; ApoPharma: Consultancy, Honoraria; Glaxo Smith Kline: Research Funding; Eli Lilly: Research Funding; Amgen: Research Funding; bluebird bio: Research Funding." @default.
• W203401045 created "2016-06-24" @default.
• W203401045 creator A5000120418 @default.
• W203401045 creator A5001334651 @default.
• W203401045 creator A5002479426 @default.
• W203401045 creator A5006173110 @default.
• W203401045 creator A5010364362 @default.
• W203401045 creator A5017011808 @default.
• W203401045 creator A5023347086 @default.
• W203401045 creator A5033829606 @default.
• W203401045 creator A5034481213 @default.
• W203401045 creator A5038535078 @default.
• W203401045 creator A5040299600 @default.
• W203401045 creator A5041095483 @default.
• W203401045 creator A5051699961 @default.
• W203401045 creator A5053216827 @default.
• W203401045 creator A5061188018 @default.
• W203401045 creator A5061551189 @default.
• W203401045 creator A5066086795 @default.
• W203401045 creator A5073597251 @default.
• W203401045 creator A5081419587 @default.
• W203401045 creator A5089575857 @default.
• W203401045 date "2013-11-15" @default.
• W203401045 modified "2023-09-28" @default.
• W203401045 title "Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial)" @default.
• W203401045 doi "https://doi.org/10.1182/blood.v122.21.543.543" @default.
• W203401045 hasPublicationYear "2013" @default.
• W203401045 type Work @default.
• W203401045 sameAs 203401045 @default.
• W203401045 citedByCount "9" @default.
• W203401045 countsByYear W2034010452014 @default.
• W203401045 countsByYear W2034010452015 @default.
• W203401045 countsByYear W2034010452016 @default.
• W203401045 countsByYear W2034010452017 @default.
• W203401045 countsByYear W2034010452019 @default.
• W203401045 countsByYear W2034010452020 @default.
• W203401045 countsByYear W2034010452021 @default.
• W203401045 crossrefType "journal-article" @default.
• W203401045 hasAuthorship W203401045A5000120418 @default.
• W203401045 hasAuthorship W203401045A5001334651 @default.
• W203401045 hasAuthorship W203401045A5002479426 @default.
• W203401045 hasAuthorship W203401045A5006173110 @default.
• W203401045 hasAuthorship W203401045A5010364362 @default.
• W203401045 hasAuthorship W203401045A5017011808 @default.
• W203401045 hasAuthorship W203401045A5023347086 @default.
• W203401045 hasAuthorship W203401045A5033829606 @default.
• W203401045 hasAuthorship W203401045A5034481213 @default.
• W203401045 hasAuthorship W203401045A5038535078 @default.
• W203401045 hasAuthorship W203401045A5040299600 @default.
• W203401045 hasAuthorship W203401045A5041095483 @default.
• W203401045 hasAuthorship W203401045A5051699961 @default.
• W203401045 hasAuthorship W203401045A5053216827 @default.
• W203401045 hasAuthorship W203401045A5061188018 @default.
• W203401045 hasAuthorship W203401045A5061551189 @default.
• W203401045 hasAuthorship W203401045A5066086795 @default.
• W203401045 hasAuthorship W203401045A5073597251 @default.
• W203401045 hasAuthorship W203401045A5081419587 @default.
• W203401045 hasAuthorship W203401045A5089575857 @default.
• W203401045 hasConcept C126322002 @default.
• W203401045 hasConcept C141071460 @default.
• W203401045 hasConcept C2776694085 @default.
• W203401045 hasConcept C2776755627 @default.
• W203401045 hasConcept C2777408962 @default.
• W203401045 hasConcept C2777799968 @default.
• W203401045 hasConcept C2778684742 @default.
• W203401045 hasConcept C2779015954 @default.
• W203401045 hasConcept C2779263901 @default.
• W203401045 hasConcept C2779968505 @default.
• W203401045 hasConcept C2781413609 @default.
• W203401045 hasConcept C2911091166 @default.
• W203401045 hasConcept C71924100 @default.
• W203401045 hasConcept C90924648 @default.
• W203401045 hasConceptScore W203401045C126322002 @default.
• W203401045 hasConceptScore W203401045C141071460 @default.
• W203401045 hasConceptScore W203401045C2776694085 @default.
• W203401045 hasConceptScore W203401045C2776755627 @default.
• W203401045 hasConceptScore W203401045C2777408962 @default.
• W203401045 hasConceptScore W203401045C2777799968 @default.
• W203401045 hasConceptScore W203401045C2778684742 @default.
• W203401045 hasConceptScore W203401045C2779015954 @default.
• W203401045 hasConceptScore W203401045C2779263901 @default.
• W203401045 hasConceptScore W203401045C2779968505 @default.
• W203401045 hasConceptScore W203401045C2781413609 @default.
• W203401045 hasConceptScore W203401045C2911091166 @default.
• W203401045 hasConceptScore W203401045C71924100 @default.
• W203401045 hasConceptScore W203401045C90924648 @default.
• W203401045 hasIssue "21" @default.
• W203401045 hasLocation W2034010451 @default.
• W203401045 hasOpenAccess W203401045 @default.
• W203401045 hasPrimaryLocation W2034010451 @default.
• W203401045 hasRelatedWork W2004645291 @default.
• W203401045 hasRelatedWork W2008973770 @default.
• W203401045 hasRelatedWork W2065648512 @default.
• W203401045 hasRelatedWork W2553236612 @default.
• W203401045 hasRelatedWork W2562459028 @default.
• W203401045 hasRelatedWork W2591212199 @default.
• W203401045 hasRelatedWork W2979467964 @default.
• W203401045 hasRelatedWork W2984964403 @default.

• next